BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
DARZALEX® (daratumumab) SC-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility March 4, 2025
Linvoseltamab BLA Accepted for FDA Review for the Treatment of R/R Multiple Myeloma; PDUFA: 10Jul2025 February 19, 2025
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. February 11, 2025
NMPA approves Sarclisa + SOC VRd in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 4, 2025
Sarclisa + VRd combo approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant February 3, 2025
Sarclisa + VRd combo approved in the EU to treat transplant-ineligible newly diagnosed multiple myeloma January 23, 2025
Simnova and Orna Expand Strategic Partnership to Include BCMA-Targeted RNA Therapeutics January 21, 2025
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 21, 2025
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 15, 2025
New Sarclisa SC formulation met co-primary endpoints in the IRAKLIA Ph 3 study in multiple myeloma January 15, 2025
Sarclisa obtains NMPA approval in China for the treatment of adult patients with R/R multiple myeloma January 14, 2025
Blenrep (belantamab mafodotin) combination accepted for priority review in China in R/R multiple myeloma December 10, 2024
Blenrep combinations accepted for review by the FDA for the treatment of R/R multiple myeloma November 26, 2024
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma November 15, 2024
Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile November 13, 2024
Applications submitted in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as SC monotherapy for high-risk smoldering multiple myeloma November 12, 2024
Orphan Drug Designation from the US FDA for LBL-034 for the Treatment of Multiple Myeloma November 12, 2024
DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the EC for patients with newly diagnosed multiple myeloma who are transplant-eligible October 29, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 22, 2024
Type II variation application to the EMA for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients October 15, 2024
